STRYKER CORP
SYKAPI behind this page
SYK Q4 2025 request
Playground key active
/api/financials?ticker=SYK&year=2025&quarter=4
Pick an endpoint and run the request.Income Statement
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Revenue | 7,171 | 6,436 | +11.4% |
Show Product Lines breakouts |
|||
| Endoscopy · MedSurg and Neurotechnology | 938 | 844 | +11.1% |
| Endoscopy · MedSurg and Neurotechnology | 207 | 162 | +27.8% |
| Endoscopy · MedSurg and Neurotechnology | 1,145 | 1,006 | +13.8% |
| Hips · Orthopaedics | 306 | 291 | +5.2% |
| Hips · Orthopaedics | 193 | 172 | +12.2% |
| Hips · Orthopaedics | 499 | 463 | +7.8% |
| Instruments · MedSurg and Neurotechnology | 748 | 627 | +19.3% |
| Instruments · MedSurg and Neurotechnology | 177 | 163 | +8.6% |
| Instruments · MedSurg and Neurotechnology | 925 | 790 | +17.1% |
| Knees · Orthopaedics | 548 | 509 | +7.7% |
| Knees · Orthopaedics | 201 | 178 | +12.9% |
| Knees · Orthopaedics | 749 | 687 | +9.0% |
| Medical · MedSurg and Neurotechnology | 1,041 | 930 | +11.9% |
| Medical · MedSurg and Neurotechnology | 243 | 212 | +14.6% |
| Medical · MedSurg and Neurotechnology | 1,284 | 1,142 | +12.4% |
| Neuro Cranial · MedSurg and Neurotechnology | 556 | 506 | +9.9% |
| Neuro Cranial · MedSurg and Neurotechnology | 113 | 97 | +16.5% |
| Neuro Cranial · MedSurg and Neurotechnology | 669 | 603 | +10.9% |
| Neurovascular · MedSurg and Neurotechnology | 294 | 137 | +114.6% |
| Neurovascular · MedSurg and Neurotechnology | 245 | 204 | +20.1% |
| Neurovascular · MedSurg and Neurotechnology | 539 | 341 | +58.1% |
| Other · Orthopaedics | 202 | 157 | +28.7% |
| Other · Orthopaedics | 65 | 65 | 0.0% |
| Other · Orthopaedics | 267 | 222 | +20.3% |
| Spine · Orthopaedics | 0 | 128 | -100.0% |
| Spine · Orthopaedics | 8 | 58 | -86.2% |
| Spine · Orthopaedics | 8 | 186 | -95.7% |
| Trauma and Extremities · Orthopaedics | 808 | 744 | +8.6% |
| Trauma and Extremities · Orthopaedics | 278 | 252 | +10.3% |
| Trauma and Extremities · Orthopaedics | 1,086 | 996 | +9.0% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology · Non Us | 985 | 838 | +17.5% |
| MedSurg and Neurotechnology · Operating Segments | 4,562 | 3,882 | +17.5% |
| MedSurg and Neurotechnology · US | 3,577 | 3,044 | +17.5% |
| Orthopaedics | 2,609 | 2,554 | +2.2% |
| Orthopaedics · Non Us | 745 | 725 | +2.8% |
| Orthopaedics · Operating Segments | 2,609 | 2,554 | +2.2% |
| Orthopaedics · US | 1,864 | 1,829 | +1.9% |
Show Geography breakouts |
|||
| Non Us | 1,730 | 1,563 | +10.7% |
| US | 5,441 | 4,873 | +11.7% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 7,171 | 6,436 | +11.4% |
| Cost of Revenue | 2,543 | 2,262 | +12.4% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology · Operating Segments | 1,697 | 1,482 | +14.5% |
| Orthopaedics · Operating Segments | 722 | 672 | +7.4% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -12 | -3 | -300.0% |
Show — breakouts |
|||
| Cost of Revenue | -12 | -3 | -300.0% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 2,419 | 2,154 | +12.3% |
| Gross Profit | 4,628 | 4,174 | +10.9% |
| Research & Development | 401 | 358 | +12.0% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology · Operating Segments | 230 | 190 | +21.1% |
| Orthopaedics · Operating Segments | 125 | 134 | -6.7% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 355 | 324 | +9.6% |
| Selling, General & Administrative | 2,227 | 2,123 | +4.9% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology · Operating Segments | 1,038 | 885 | +17.3% |
| Orthopaedics · Operating Segments | 800 | 844 | -5.2% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1,838 | 1,729 | +6.3% |
| Amortization Of Intangible Assets | 189 | 156 | +21.2% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 189 | 156 | +21.2% |
| Asset Impairment Charges | 7 | 956 | -99.3% |
| Operating Expenses | 2,824 | 3,593 | -21.4% |
| Operating Income | 1,804 | 581 | +210.5% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology · Operating Segments | 1,531 | 1,288 | +18.9% |
| Orthopaedics · Operating Segments | 852 | 794 | +7.3% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 2,383 | 2,082 | +14.5% |
| Non-Operating Income (Expense) | 508 | 356 | +42.7% |
Show Equity Components breakouts |
|||
| Accumulated Translation Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -11 | -11 | 0.0% |
Show — breakouts |
|||
| Non-Operating Income (Expense) | -42 | -32 | -31.2% |
| Income Before Taxes | 1,705 | 528 | +222.9% |
| Income Tax Expense (Benefit) | 856 | -18 | +4855.6% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | 9 | 15 | -40.0% |
| Accumulated Translation Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | 18 | 14 | +28.6% |
Show — breakouts |
|||
| Income Tax Expense (Benefit) | 27 | 29 | -6.9% |
| Net Income | 849 | 546 | +55.5% |
Show Equity Components breakouts |
|||
| Retained Earnings | 849 | 546 | +55.5% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 1,804 | 581 | +210.5% |
| EPS (Basic) | 2.22 | 1.44 | +54.2% |
| EPS (Diluted) | 2.2 | 1.41 | +56.0% |
| Wtd Avg Shares (Basic) | 0.1 | 0.1 | -0.0% |
| Weighted Average Number Diluted Shares Outstanding Adjustment | -0.1 | 0.1 | -200.0% |
| Wtd Avg Shares (Diluted) | 0 | 0.2 | -100.0% |
| Comprehensive Income | 928 | 798 | +16.3% |
| Foreign Currency Transaction Gain Loss Before Tax (Q) | — | — | — |
Show Derivative Risk breakouts |
|||
| Foreign Exchange Contract | 25 | 21 | +19.0% |
| Foreign Exchange Contract · Cost Of Sales | 12 | 3 | +300.0% |
Show — breakouts |
|||
| Foreign Currency Transaction Gain Loss Before Tax | 13 | 2 | +550.0% |
| Foreign Currency Transaction Gain Loss Before Tax | 2 | 7 | -71.4% |
Balance Sheet
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 4,011 | 3,652 | +9.8% |
| Available For Sale Securities Debt Securities Current | 89 | 91 | -2.2% |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 | 89 | 91 | -2.2% |
| Fair Value Inputs Level2 · Asset Backed Securities | 52 | 53 | -1.9% |
| Fair Value Inputs Level2 · US Treasury Securities | 37 | 34 | +8.8% |
| Accounts Receivable | 4,039 | 3,987 | +1.3% |
| Inventory Raw Materials And Supplies Net Of Reserves | 1,349 | 1,147 | +17.6% |
| Inventory Work In Process Net Of Reserves | 415 | 336 | +23.5% |
| Inventory Finished Goods Net Of Reserves | 3,546 | 3,291 | +7.7% |
| Inventory | 5,310 | 4,774 | +11.2% |
| Prepaid Expense Current | 1,306 | 1,593 | -18.0% |
| Total Current Assets | 14,755 | 14,847 | -0.6% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 3,876 | 3,448 | +12.4% |
Show Geography breakouts |
|||
| Asia Pacific | 97 | 75 | +29.3% |
| EMEA | 1,562 | 1,260 | +24.0% |
| Other foreign countries | 133 | 116 | +14.7% |
| US | 2,084 | 1,997 | +4.4% |
| Goodwill | 19,291 | 15,855 | +21.7% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology | 12,556 | 9,208 | +36.4% |
| Orthopaedics | 6,735 | 6,647 | +1.3% |
Show Business Acquisition breakouts |
|||
| Inari | 3,191 | — | — |
Show Reporting Unit breakouts |
|||
| Peripheral Vascular Reporting Unit | 3,203 | — | — |
| Deferred Tax Assets | 1,098 | 1,742 | -37.0% |
| Other Non-Current Assets | 3,143 | 2,684 | +17.1% |
| Total Assets | 47,844 | 42,971 | +11.3% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology · Operating Segments | 27,647 | 23,115 | +19.6% |
| Orthopaedics · Operating Segments | 18,641 | 18,507 | +0.7% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 1,556 | 1,349 | +15.3% |
| Operating Segments | 46,288 | 41,622 | +11.2% |
| Operating Lease Right-of-Use Assets | 519 | 516 | +0.6% |
| Intangible Assets | 5,681 | 4,395 | +29.3% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 1,581 | 1,419 | +11.4% |
| Developed Technology Rights | 3,843 | 2,767 | +38.9% |
| In Process Research And Development | 34 | 34 | 0.0% |
| Other Intangible Assets | 71 | 1 | +7000.0% |
| Patents | 13 | 17 | -23.5% |
| Trademarks | 139 | 157 | -11.5% |
| Other Assets | |||
| Property Plant And Equipment Gross | 7,537 | 6,683 | +12.8% |
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 3,661 | 3,235 | +13.2% |
| Intangible Assets Net Excluding Goodwill | 5,681 | 4,395 | +29.3% |
| Current Liabilities | |||
| Accounts Payable Trade Current | 1,799 | 1,679 | +7.1% |
| Employee Related Liabilities Current | 1,595 | 1,403 | +13.7% |
| Accrued Income Taxes Current | 418 | 539 | -22.4% |
| Dividends Payable Current | 337 | 320 | +5.3% |
| Other Liabilities Current | 2,645 | 2,266 | +16.7% |
| Debt Current | 1,000 | 1,409 | -29.0% |
| Total Current Liabilities | 7,794 | 7,616 | +2.3% |
| Non-Current Liabilities | |||
| Long-Term Debt | 14,859 | 12,188 | +21.9% |
| Accrued Income Taxes Noncurrent | 402 | 349 | +15.2% |
| Other Non-Current Liabilities | 2,369 | 2,184 | +8.5% |
| Total Liabilities | 25,424 | 22,337 | +13.8% |
| Operating Lease Liabilities | 348 | 379 | -8.2% |
| Deferred Tax Liabilities | -137 | -82 | -67.1% |
| Stockholders' Equity | |||
| Common Stock Value Outstanding | 38 | 38 | 0.0% |
| Additional Paid In Capital Common Stock | 2,597 | 2,361 | +10.0% |
| Retained Earnings | 20,472 | 18,528 | +10.5% |
| Accumulated Other Comprehensive Income | -687 | -293 | -134.5% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 22,420 | 20,634 | +8.7% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 70 | 4 | +1650.0% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 42 | 31 | +35.5% |
| Accumulated Other Comprehensive Income | -687 | -293 | -134.5% |
| Accumulated Translation Adjustment | -799 | -328 | -143.6% |
| Additional Paid In Capital | 2,597 | 2,361 | +10.0% |
| Aoci Including Portion Attributable To Noncontrolling Interest | -687 | -293 | -134.5% |
| Common Stock | 38 | 38 | 0.0% |
| Retained Earnings | 20,472 | 18,528 | +10.5% |
| Total Liabilities & Equity | 47,844 | 42,971 | +11.3% |
| Common Stock Par Or Stated Value Per Share | 0.1 | 0.1 | 0.0% |
| Land Buildings And Improvements Gross | 1,793 | 1,627 | +10.2% |
| Machinery And Equipment Gross | 5,744 | 5,056 | +13.6% |
Cash Flow Statement
| Metric | YTD Q4 2025 | YTD Q4 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 127 | 108 | +17.6% |
| Stock-Based Compensation | 48 | 45 | +6.7% |
| Inventory Stepped Up To Fair Value At Acquisition (Q) | — | — | — |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 13 | 8 | +62.5% |
| Deferred Income Taxes | 201 | -349 | +157.6% |
| Change in Accounts Receivable | -397 | -388 | -2.3% |
| Change in Inventory | 76 | 156 | -51.3% |
| Increase Decrease In Accounts Payable Trade | 299 | 395 | -24.3% |
| Increase Decrease In Accrued Liabilities | 396 | 298 | +32.9% |
| Increase Decrease In Accrued Income Taxes Payable | 432 | 120 | +260.0% |
| Increase Decrease In Other Operating Capital Net | -97 | -120 | +19.2% |
| Net Cash from Operations | 2,143 | 1,931 | +11.0% |
| Depreciation & Amortization | 416 | 346 | +20.2% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology · Operating Segments | 66 | 38 | +73.7% |
| Orthopaedics · Operating Segments | 110 | 108 | +1.9% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 51 | 44 | +15.9% |
| Operating Segments | 176 | 146 | +20.5% |
| Investing Activities | |||
| Payments To Acquire Businesses Net Of Cash Acquired | -10 | -30 | +66.7% |
| Payments For Proceeds From Short Term Investments | 0 | 0 | — |
| Capital Expenditures | -268 | -266 | -0.8% |
| Other Investing Activities | -19 | 91 | -120.9% |
| Net Cash from Investing | -305 | -303 | -0.7% |
| Financing Activities | |||
| Proceeds From Issuance Of Long Term Debt | 0 | 0 | — |
| Repayments Of Long Term Debt | -750 | -1,438 | +47.8% |
| Payments Of Dividends | -321 | -305 | -5.2% |
| Tax Withholding for Share Compensation | -17 | -49 | +65.3% |
| Proceeds From Payments For Other Financing Activities | -4 | -2 | -100.0% |
| Net Cash from Financing | -1,093 | -1,794 | +39.1% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 10 | -32 | +131.2% |
| Net Change in Cash | 755 | -198 | +481.3% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 4,011 | 3,652 | +9.8% |
Values in millions USD. Source: SEC EDGAR 10-K filing.